India Needs Doctors, Nurses, Health Insurance, PHU’s & Quality free Medicines- - Pharmaleaders -

Sept. 2, 2012 - PRLog -- India Needs Doctors, Nurses, Health Insurance, PHU’s & Quality free Medicines- - 5th Annual Pharmaceutical Leadership Summit

Industry Veterans Dr Mukesh Batra, Mr. Kewal Handa, Dr B.R Shetty, Dr Mukesh Hariawala,Dr Kannan Vishwanath, Shivkumar Kunchithapatham, Dr Rajaram Samant, Dr Rashmi Shetty, Dr Shuba Dharmana, François Licoppe, V.Veerramani, Dr Mahesh Burande to address

Maharashtra, Mumbai, 2nd September 2012: India needs doctors, nurses and health insurance, Public Healthcare Units, Free Medicines for poor &  & moreover the brand India Pharma Image cant be realized unless & until a strong healthcare policy is in place & healthcare reforms to address the challenges of getting quality medicines at affordable price, feel the illustrious list of speakers who will gather to debate at historic & prestigious 5th Annual Pharmaceutical Leadership Summit & Business Leadership Awards 2012 ( www.asiapharmaleaders.com )( www.breakfastnews.tv ). Pharmaleaders, a Mumbai based healthcare media group (www.pharmaleaders.co.in ) in association with country’s biggest trade bodies & associations is debating the critical issues on 21st September 2012 on a Theme “Brand India Pharma, Beyond Generics. Leading with Resilience: Coming Back from Challenge and Heading Towards Super-power Status”.

   India has just seven doctors per 10,000 people, while China has 14 per 10,000
   Less than 23 percent of Indians are covered by policies
   95 percent of the population in China are  covered by some sort of insurance, India is nil
   There are just Eleven  hospital beds per 10,000 people in India, compared with 41 per 10,000 in China.
   Access to basic Medicine by the large chunk of Indian Population is still an issue.
   Quality Medicines at Affordable Prices is still a slogan.

The Leadership Summit will witness the who’s & Who’s of Indian Healthcare Industry with 10 plenary sessions to cover the burning issues of the sector such as Challenges and Opportunities for Indian Pharma Industry to become Pharma Superpower in 2020 by  Dr Mahesh Burande, Hon Director,Institute of  Pharmaceutical Education and Research (IPER). Branded Formulations VS Branded Generics, 2012 Pharmaceutical Diversification Trends by  Kewal Handa, Ex Managing Director, Pfizer Ltd. & Wyeth Ltd, Making of Dr Batras Brand,  Indian Experience VS Global Challenges by Dr Mukesh Batra.Founder Chairman, Dr Batra’s Positive Clinic, Are We Ready For A “Mechanical Artificial Heart For Indian Patients by Dr Mukesh Hariawala, Cardiac Surgeon & Healthcare Economist, Harvard Medical School Affiliated Hospitals, Boston, USA. Regulatory Challenges of Indian Pharmaceutical companies. A CEO’s Perspective by Dr. Shenaz Khaleeli ,Co- Founder & Technical Director, PharmaLeaf India Pvt Ltd, Delivering value in the Supply Chain by Sue Arden, VP Life Sciences & Healthcare.  DP DHL, Singapore, Neutraceutical & OTC Sector: The European Market Challenge by François Licoppe, CEO,Eubage Laboratory, Belgium, Indian Pharma Industry : Challenges & Key Issues in partnership, Alliances & Co-Marketing by  Shivkumar Kunchithapatham, Managing Director,  Eisai Pharmaceuticals India Private Limited, Innovative Trends in Facial Aesthetics – Indian Challenges with Global Experiments by Dr. Shuba Dharmana Cosmetic Dermatologist, Laser Specialist, Hair Transplant Surgeon, CEO Dr.Shuba Skin & Laser Clinic. The Event will see a high powered panel discussion on Globalization of Indian Brands: Key Challenges & Opportunities by the Experts such as Mr. Kersi Tavadia, CIO, Bombay Stock Exchange Limited,.

Mr.Rakesh Bhargava, Chairman, Fresenius Kabi Oncology Ltd, Dr Shuba Dharmana, Dermatologist, Hair Transplant surgeon & Aesthetic & Laser, Dr Mahesh Burande, Hon.Director Institute of Pharmaceutical Education and Research & Consultant, Dr Rajaram Samant, Founder Chairman, Akumentis Healthcare Ltd, Mr S.V.Veerramani, CMD, Fourrts(India) Laboratories Pvt Ltd, Dr. B.R. Shetty, Founder,Managing Director & CEO, NMC Healthcare, Abu Dhabi, U.A.E, Dr Mukesh Batra, Chairman, Dr Batra's Positive Health,   Dr Rashmi Shetty, Cosmetologist, and pioneer and leading expert for Non-Surgical Aesthetic Medicine,  Dr Kannan Vishwanath, VC, MD, Aanjaneya Lifecare Ltd.

Speaking on the high panel speaker & battery of experts who will gather to speak at Pharmaleaders Annual Meet, Satya Brahma, Editor-In-Chief of Breakfast news ( www.breakfastnews.tv ( & Pharmaleaders said “Unlike Europe such as Canada & others, Healthcare is given a top priority & the reforms are on top of the Agenda & the respective Governments are concerned about it, In India Healthcare is  not delivered through a publicly funded health care system & lacks transparency & synergy of systems, poor policies arising out of a fractured mandate, Coalition  government at the Center are paralyzing Indian healthcare sector”. This Conglometer will address the core Issues added satya Brahma.
The Indian Pharma industry accounts for ~20% (volume terms) of the global generics industry. During the 11th plan period, the domestic pharma market grew at 14% CAGR and exports grew at 19% CAGR with anti infective, anti asthmatic and anti hypertensive being the major therapeutic categories. USA, Russia, Germany, Austria and UK are the top export destinations with USA alone accounting for almost 20% of total exports. Although the industry is fragmented, the large and medium sized pharma companies contribute to ~75% of the domestic sales and over 90% of exports.  

The overall pharmaceutical industry was pegged at Rs 1,000 billion (~USD 20 billion) with the domestic pharma industry at over Rs 600 billion (~USD 12 billion) in 2009-10. The bulk drugs contributed to about Rs 420 billion (USD 8.4 billion). The country has about 10,563 manufacturing units with about 300 large and medium units and remaining in the small scale and unorganized sector.   The Department of Pharma in its 12th plan aims to increase the size of the industry to USD 60 billion with exports contributing to over USD 25 billion. The contribution of bulk drugs is aimed at USD 28 billion (47% contribution). About USD 300 billion worth of patented drugs are expected to become generic by 2015 and this would a major driving factor for our exports.

The Leadership Event will felicitate the shining stars of Indian Healthcare sector at 5th Annual Pharmaceutical Leadership Awards 2012.